Table 3 Sensitivity and specificity data for faecal calprotectin in adenomas and advanced adenomas
Author | Year | n | Cut-off | Standard-ised cut-off | Sens (%) | Spec (%) | PPV (%) | NPV (%) | Comment | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
Total | Adenoma (%) | AA (%) | |||||||||
Adenomas | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Kronborg | 2000 | 814 | 203 (24.9) | – | 10 mg/l | 50 | 43.0 | – | – | – |  |
Tibble | 2001 | 233 | 29 (12.4) | – | 10 mg/l | 50 | 55.0 | 85.2* | 45.7* | 89.3* |  |
Kristinsson | 2001 | 237 | 73 (30.8) | 17 (7.2) | 10Â mg/l | 50 | 56.2 | 47.4 | 40.6* | 62.8* | Â |
| Â | Â | Â | Â | Â | 15Â mg/l | 75 | 45.2 | 59.6 | 41.8* | 63.0* | Â |
| Â | Â | Â | Â | Â | 20Â mg/l | 100 | 31.5 | 71.1 | 41.1* | 61.8* | Â |
Damms | 2008 | 140 | 29 (20.7) | – | 50 μg/g | 50 | 55.0 | 79.0 | 57.0 | 77.0 |  |
Kalimutho | 2011 | 192 | 69 (35.9) | 34 (17.7) | 45.8Â ng/ml | Â | 28.0 | 25.0* | 21.0* | 34.0* | Â |
Widlak | 2016 | 430 | 42 (9.8) | – | 50 μg/g | 50 | 43.0 | 56.0 | 10.0* | 90.0* |  |
Rutka | 2016 | 95 | 36 (37.9) | 20 (21.1) |  |  | – | – | – | – | Faecal calprotectin significantly lower in low-risk adenoma compared to CRC |
Advanced adenomas | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Hoff | 2004 | 2321 | – | 195 (8.4) | 50 μg/g | 50 | 26.7* | 76.1* | 12.5* | 89.0* |  |
Mowat | 2015 | 755 | – | 41 (5.4) | 50 μg/g | 50 | 58.5 | 37.8 | 5.3 | 93.8 |  |
|  |  |  |  |  | 200 μg/g | 200 | 19.5 | 73.7 | 4.3 | 93.8 |  |
Lue | 2020 | 404 | 41 (10.1) | 39 (10) | 50 μg/g | 50 | 66.6 | 48.8 | 12.2 | 93.2 |  |
Parente | 2012 | 280 | – | 85 (30.4) |  |  | – | – | – | – | Significant differences between faecal calprotectin in both CRC and AA, and normal and AA (p < 0.001) |
Turvill | 2016 | 654 | – | 33 (5.0) |  |  | – | – | – | – | 30/33 (90.9%) patients with AA had a high faecal calprotectin |